Navigation Links
Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
Date:1/17/2013

Davis, California and Seoul, South Korea (PRWEB) January 17, 2013

Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are pleased to announce the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry. BioCore, the first bioanalytical CRO in Korea, has an established reputation for quality service and a customer base that extends throughout Asia. This relationship expands BioCore’s portfolio, adding EZVS’s Accelerator Mass Spectrometry (AMS) based services to their suite of advanced offerings, and facilitates EZVS’s entry into the rapidly growing Asian pharmaceutical market.

AMS is an ultrasensitive radiocarbon detection platform that complements other tools available to the pharmaceutical scientist. “Atom counting” sensitivity enable new avenues of clinical drug development in ways that were not previously possible. For example, microdosing allows the behavior of any drug to be studied with almost no risk of side effects. BioCore President and CEO Hyung Sik Choie comments, “Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are pleased to announce the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry. BioCore, the first bioanalytical CRO in Korea, has an established reputation for quality service and a customer base that extends throughout Asia. This relationship expands BioCore’s portfolio, adding EZVS’s Accelerator Mass Spectrometry (AMS) based services to their suite of advanced offerings, and facilitates EZVS’s entry into the rapidly growing Asian pharmaceutical market.

AMS is an ultrasensitive radiocarbon detection platform that complements other tools available to the pharmaceutical scientist. “Atom counting” sensitivity enable new avenues of clinical drug development in ways that were not previously possible. For example, microdosing allows the behavior of any drug to be studied with almost no risk of side effects. BioCore President and CEO Hyung Sik Choie comments, “This alliance brings capabilities through the BioCore interface with immediate benefit to the Korean pharmaceutical community by reducing the timeline to bring new drugs to market.” These studies, while approved under FDA and ICH guidances, are not currently being performed in Korea due to the lack of bio accelerator expertise.

EZVS’s team of experts includes the founders of applied AMS methods for biological determinations and innovators of next generation BioMICADAS AMS technology. Dr. Stephen Dueker, EZVS CSO, stated, “We are very pleased to be represented by BioCore. Alignment with the foremost CRO in Korea provides EZVS presence in Asia and strengthens our credibility as we introduce the benefits of applied AMS into new territory.” The agreement combines the technical expertise of both companies to deliver solutions designed to streamline the drug development process and accelerate commercialization to pharmaceutical sponsors.

About BioCore
BioCore is South Korea's largest provider of bioanalytical liquid chromatography-tandem mass spectrometry (LC/MS/MS) services. BioCore was South Korea's first GLP-complaint centralized bioanalytical CRO (2005) and first to be certified by the Korea Food and Drug Administration as a Bioequivalence Testing Institution (2008).

About EZVS
Eckert & Ziegler Vitalea Science is an integrated provider of isotopes and isotope measurement and calibration services with the Davis, California facility dedicated to GLP level bioanalysis. Founded in 2003, by researchers from the University of California, EZVS is the first U.S.-based bioanalytical contract research organization dedicated to providing services for exploring the pharmacokinetics and metabolism of drug candidates directly in humans and non-clinical species using AMS, both prior to and as part of phase I clinical trials. In our Davis, CA facility, we utilize the BioMICADAS, the only AMS instrument purpose-built to address the specific needs of the pharmaceutical industry.

For further information, please contact:

Eckert & Ziegler Vitalea Science
2121 Second St. Suite B101
Davis, CA 95618
T: +1.530.341.0200
F: +1.530.341.0299
http://www.vitaleascience.com

Media contact:
Ann Hoffman
T: +1.801.706.2237
E: ahoffman(at)vitaleascience(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10328760.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sustainable Valley Technology Group Provides Technology Innovation Grant To Help Researchers & Start-Ups With Funding, Business Support, Equipment & Facilities
2. Precision Coating to Showcase Next Generation Coating Deposition Technology at MD&M West Show in Anaheim, California
3. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
4. iLuv Introducing NFC & Qi-Certified Technology to Bluetooth Speaker Lineup at 2013 CES
5. Market for Biologic Imaging Reagents and Medical Imaging & Diagnosing Analyzed in New Research Reports at ReportsnReports.com
6. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
7. DuPont Tate & Lyle Bio Products Announces Innovation Award Program
8. LA Dental Bone Graft Substitute & Other Biomaterials Market Reviewed in New iData Research Report Available at MarketPublishers.com
9. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
10. Brownfield Science & Technology Inc. Honored for Professional Services Excellence
11. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @ RnRMarketResearch.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... May 6, 2016 Recent studies show that ... prescription pain medication when treating certain types of pain. ... therapy, doctors can go right to the source instead ... an educational organization, provides physician training about the benefits ... feature to find physicians across the United ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... their most recent release, Clinical Studio Version 4.1, greatly improves performance of the ... oncology, where protocols often generate tremendous volumes of data to be collected on ...
(Date:5/6/2016)... ... May 06, 2016 , ... This June 3-6, SonoDepot ... an exclusive sales and service provider of the ALPINION line, reps will educate attendees ... conference for healthcare technology management. The event draws more than 2,200 biomedical equipment technicians, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... agreement to acquire Algynomics, a research-stage pain diagnostics company. The Algynomics ... at increased risk for the development of chronic pain, which will allow targeted ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):